Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS

Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.

Investigating the role of the microbiota in checkpoint inhibitor response.

Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.

CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.

Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.

Bringing together the experts to discuss the timeline of autoimmune disease therapeutics.

What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?

Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.

Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.

Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.

Experts discuss elusively successful therapies and the rising costs that come with new technologies.

RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field.

The power of the genome has enormous implications for immunotherapy

What is the future of precision medicine for immuno-oncology, and how can we achieve it? In this Insight Article, we sat down with senior representatives from the University of Michigan, the Beth Israel Deaconess Medical Center / Harvard Medical School, and The Institute of Cancer Research, London, to discover more about harnessing the potential of spatial biology and predictive biomarkers to achieve targeted results.

Improving preclinical modelling to translate drugs to the clinic is one of the key priorities in immunotherapy and immuno-oncology today. We sat down with senior representatives from GemPharmatech and MiNA Therapeutics to find out how best to develop the next generation of preclinical modelling.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our first ever Immuno Discussion Group addressing ‘Understanding The Tumour Microenvironment With Advanced Technologies’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

Tumour associated macrophages are critical drivers in cancer progression and metastasis. Clinical studies now suggest that changing polarisation of macrophages can significantly improve immuno-oncology response. Speaking with senior representatives from Verseau Therapeutics, Pathios Therapeutics, and Faron Pharmaceuticals, we delve into some of the latest techniques in macrophage targeting.

The activation of GPR65 on immune cells by the acidic tumour microenvironment and the resultant immunosuppression may be one of the principal reasons many cancers do not respond to current T Cell checkpoint therapies. Chief Executive Officer Stuart Hughes delves into some of Pathios Therapeutics recent developments in macrophage conditioning and its promise to enable a successful anti-tumour immune response.

At the 2021 Immuno Week: Online event, we sat down with an advisory board comprised of key figures from some of the top biotech companies and research institutions to discuss the acute need for improved combination therapies and predictive biomarkers in immuno-oncology.